Amgen (AMGN)'s future prospects are seen as promising, with several financial firms making significant investments in the healthcare giant.
Morgan Stanley trimmed the price target for AMGN as policy risks reportedly eased, while
HSBC expressed increased bullishness on the company's prospects leading into 2026. Despite some sales of shares by companies like Swedbank AB and Revolve Wealth Partners LLC, a growing number of investors like Carnegie Investment Counsel, Avanza Fonder AB, and Farther Finance Advisors LLC are pouring into the stock, indicating market confidence. Moreover, AMGN is collaborating with the U.S. government to help reduce the cost of medications for American consumers, a move that will potentially strengthen its market position. On its outlook, AMGN's new drug approval for CD19-targeted gMG alters its investment story. Furthermore, some believe that the company's intrinsic value is significantly higher than its current share price. Despite challenges, AMGN has consistently outperformed the stock market, driven by its strong financial performance, innovative product line, and positive trial results.
Amgen AMGN News Analytics from Thu, 17 Jul 2025 07:00:00 GMT to Sat, 27 Dec 2025 17:34:00 GMT -
Rating 8
- Innovation 6
- Information 9
- Rumor 4
